Jump to navigation

Delays to Mpox vaccine supplies raise concerns

Anger as WHO’s slow response shows lessons learned from the Covid-19 pandemic have not brought much change

The slow pace of delivering Mpox vaccines and limited funding for scientific research into the severity of strains suggests that Africa is little more prepared for Mpox than it was for Covid-19 (AC Vol 61 No 20, Paths out of the pandemic).

There is frustration and anger that the World Health Organization (WHO) did not start the process needed to give African countries easy access to large quantities of vaccines via international agencies until August. That has left African states and the Africa Centres for Disease Control and Prevention (Africa CDC) requesting donations of Mpox vaccines from Bavarian Nordic, KM Biologics and wealthy states, a repeat of the situation during Covid-19 that left African states – without the capacity to mass produce vaccines – at the back of the queue.

The WHO has now requested information on Mpox vaccines from the two manufacturers, allowing them to obtain emergency licenses to sell them to the United Nations, Global Alliance for Vaccinations and Immunisations (GAVI), and individual countries.

So far, pledged vaccine donations from Europe and the United States are in the hundreds of thousands. The first batches of vaccines are expected to be ready in Congo-Kinshasa and elsewhere this week despite having already been available to treat cases in Europe.

Africa CDC reckons that 10 million vaccines will be needed by the end of 2025 at an average price of US$100 per dose.

On 26 August, the WHO launched a six-month plan starting in September, to help stop outbreaks of Mpox transmission, including increasing workers in affected countries. It aims to improve fair access to vaccines, particularly in Congo-K and other African countries hardest hit by the outbreak. The WHO has called for $135m in funding, a distinctly meagre sum.



Related Articles

Paths out of the pandemic

Dire predictions of the toll in Africa from Covid-19 were overblown but disinformation is threatening public health initiatives

Back in March, it was the lull before the storm, with predictions of three million deaths from Covid-19 in Africa. Thankfully, the storm never came. Today, it is...


Vaccine shortfall risks spread of deadly new mpox strain

Disputes over pricing between Big Pharma and African states delayed response as did poor testing and surveillance

It took less than a year for the virus to resurface in Congo-Kinshasa after the World Health Organization (WHO) had announced in May 2023 that the global mpox...


Sparring for a jab

Trade and production deals may help the region’s vaccination drive in the short term more than lobbying for changes to the IP and patent laws

The challenge to access vaccines against Covid-19 is not just an African problem, it is a global battle. But it has shone a spotlight on the complexities that...

READ FOR FREE

Paths out of the pandemic

Dire predictions of the toll in Africa from Covid-19 were overblown but disinformation is threatening public health initiatives

Back in March, it was the lull before the storm, with predictions of three million deaths from Covid-19 in Africa. Thankfully, the storm never came. Today, it is...


The pandemic's collateral damage

The focus on the coronavirus, coupled with logistical problems, is drawing resources from the fight against Africa’s other serious diseases

Covid-19 is serious enough, but in Africa the unintended consequences of diverting health service resources may be even worse. 'The knock-on effects of Covid-19 on the fight against...